GlassScriptPhysician profile
Edward Eugene Metzger
NPI 1013972462
$3,136.98
in general payments reported to CMS, 2019-2025
19 companies · $1,326 in 2025
The $1,326 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $23.04 · 2021: $198 · 2022: $538 · 2023: $445 · 2024: $606 · 2025: $1,326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,378.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,185.58 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $497.18 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $451.76 | 2022-2025 | Tremfya, Stelara, Simponi |
| Regeneron Healthcare Solutions, INC. | $163.57 | 2025 | Dupixent |
| Aimmune Therapeutics, INC. | $147.01 | 2024-2025 | Zenpep |
| Ardelyx, INC. | $143.91 | 2023-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.69 | 2021-2025 | Xifaxan |
| Ipsen Biopharmaceuticals, INC | $108.87 | 2024-2025 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $81.42 | 2021-2025 | Ocaliva |
| Braintree Laboratories, INC. | $48.91 | 2020-2022 | |
| Nestle Healthcare Nutrition INC. | $40.11 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $35.00 | 2023-2024 | Dificid |
| Innovation Technologies INC | $23.33 | 2025 | Irrisept |
| Medtronic, INC. | $21.88 | 2024 | Gi Genius |
| Lilly USA, LLC | $18.89 | 2025 | Omvoh |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $17.71 | 2025 | Rezdiffra |
| Novo Nordisk INC | $15.13 | 2025 | Wegovy |
| Blueprint Medicines Corporation | $15.07 | 2024 | Ayvakit |
| Olympus America INC. | $11.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Metzger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.